Clinical Trials Logo

HER-2 Protein Overexpression clinical trials

View clinical trials related to HER-2 Protein Overexpression.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03613168 Completed - Cholangiocarcinoma Clinical Trials

Trastuzumab in HER2-positive Biliary Tract Cancer

BILHER
Start date: June 1, 2019
Phase: Phase 2
Study type: Interventional

Trastuzumab is approved for the treatment of HER2-positive breast cancer and gastric cancer. The recent study showed that HER2 overexpression or amplification is noted about 5-15% of total biliary tract cancer patients. The aim of this study is to evaluate the efficacy and safety of trastuzumab in the combination of current standard gemcitabine plus cisplatin.